Proskuriakova Ekaterina, Aryal Barun, Khan Sarah, Sanchez Danielle, Moss Joseph, Khosla Pam
Internal Medicine, Mount Sinai Hospital, Chicago, USA.
Hematology and Oncology, Mount Sinai Hospital, Chicago, USA.
Cureus. 2024 May 30;16(5):e61355. doi: 10.7759/cureus.61355. eCollection 2024 May.
Brain metastasis is a rare complication of ovarian cancer, always found at the advanced stage. Even though different multimodal approaches are available, including surgical intervention and radiotherapy, there are no official guidelines for handling this serious complication. Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors are a group of medications initially used for maintenance therapy in platinum-sensitive recurrent ovarian cancer. Niraparib has shown some efficacy in patients with brain metastasis due to its unique properties of penetrating the blood-brain barrier. Here, we present the case of a 51-year-old patient with advanced ovarian cancer with no germline breast cancer susceptibility gene (BRCA) mutations. Despite undergoing surgery and multiple rounds of chemotherapy, the patient's condition worsened, culminating in brain metastasis. Given her neurological issues, radiotherapy was not an option, prompting the initiation of a 300 mg dose of niraparib. To date, only sporadic case reports in the literature have described patients with ovarian cancer treated with niraparib and complicated by brain metastasis. Our case is unique because it is the first case of a patient with the endometrioid type of ovarian cancer.
脑转移是卵巢癌的一种罕见并发症，通常在晚期发现。尽管有多种多模式治疗方法可供选择，包括手术干预和放疗，但对于处理这种严重并发症尚无官方指南。聚（腺苷二磷酸 - 核糖）聚合酶（PARP）抑制剂是一类最初用于铂敏感复发性卵巢癌维持治疗的药物。尼拉帕尼因其穿透血脑屏障的独特特性，在脑转移患者中显示出一定疗效。在此，我们报告一例51岁的晚期卵巢癌患者，其无种系乳腺癌易感基因（BRCA）突变。尽管接受了手术和多轮化疗，患者病情仍恶化，最终发生脑转移。鉴于其神经系统问题，放疗不是选择，于是开始给予300毫克剂量的尼拉帕尼。迄今为止，文献中仅有零星病例报告描述了接受尼拉帕尼治疗并并发脑转移的卵巢癌患者。我们的病例独特之处在于这是第一例子宫内膜样型卵巢癌患者。
